Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | CRBP |
---|---|---|
08:32 ET | 1690 | 16.12 |
08:34 ET | 3171 | 16.36 |
08:36 ET | 300 | 16.455 |
08:38 ET | 100 | 16.51 |
08:41 ET | 325 | 16.4 |
08:50 ET | 3700 | 16.505 |
08:52 ET | 1812 | 16.49 |
08:54 ET | 1000 | 16.49 |
08:56 ET | 540 | 16.49 |
08:59 ET | 1740 | 16.595 |
09:01 ET | 2068 | 16.6229 |
09:03 ET | 200 | 16.68 |
09:06 ET | 4627 | 16.575 |
09:14 ET | 1016 | 16.74 |
09:15 ET | 550 | 16.7 |
09:17 ET | 3600 | 16.63 |
09:19 ET | 665 | 16.7 |
09:21 ET | 339 | 16.8 |
09:24 ET | 200 | 16.87 |
09:26 ET | 200 | 16.9 |
09:30 ET | 194 | 16.8885 |
09:32 ET | 100 | 16.91 |
09:35 ET | 100 | 16.84 |
09:37 ET | 200 | 16.8231 |
09:39 ET | 1630 | 16.79 |
09:44 ET | 200 | 16.7 |
09:51 ET | 4544 | 16.68 |
09:53 ET | 100 | 16.7154 |
09:55 ET | 2188 | 16.63 |
10:04 ET | 353 | 16.5 |
10:09 ET | 100 | 16.5 |
10:13 ET | 200 | 16.58 |
10:15 ET | 100 | 16.58 |
10:18 ET | 277 | 16.58 |
10:26 ET | 211 | 16.51 |
10:27 ET | 547 | 16.545 |
10:31 ET | 117 | 16.54 |
10:38 ET | 100 | 16.53 |
10:40 ET | 100 | 16.53 |
10:42 ET | 100 | 16.53 |
10:51 ET | 600 | 16.44 |
10:54 ET | 100 | 16.44 |
10:58 ET | 158 | 16.39 |
11:03 ET | 300 | 16.49 |
11:05 ET | 100 | 16.54 |
11:12 ET | 1890 | 16.48 |
11:14 ET | 100 | 16.5 |
11:18 ET | 697 | 16.53 |
11:21 ET | 200 | 16.53 |
11:23 ET | 100 | 16.49 |
11:30 ET | 400 | 16.48 |
11:34 ET | 500 | 16.48 |
11:36 ET | 100 | 16.51 |
11:38 ET | 1000 | 16.5 |
11:39 ET | 137 | 16.52 |
11:41 ET | 200 | 16.56 |
11:43 ET | 1400 | 16.48 |
11:45 ET | 100 | 16.37 |
11:48 ET | 200 | 16.36 |
11:50 ET | 200 | 16.35 |
11:54 ET | 300 | 16.41 |
11:56 ET | 802 | 16.34 |
11:57 ET | 341 | 16.2845 |
11:59 ET | 1409 | 16.335 |
12:01 ET | 1931 | 16.35 |
12:08 ET | 200 | 16.36 |
12:10 ET | 709 | 16.34 |
12:12 ET | 500 | 16.37 |
12:15 ET | 2459 | 16.37 |
12:17 ET | 1040 | 16.34 |
12:19 ET | 700 | 16.35 |
12:21 ET | 500 | 16.39 |
12:24 ET | 1300 | 16.38 |
12:28 ET | 200 | 16.37 |
12:30 ET | 100 | 16.41 |
12:32 ET | 200 | 16.37 |
12:33 ET | 920 | 16.37 |
12:35 ET | 1396 | 16.41 |
12:37 ET | 125 | 16.425 |
12:39 ET | 200 | 16.48 |
12:42 ET | 2931 | 16.45 |
12:46 ET | 100 | 16.46 |
12:48 ET | 100 | 16.4 |
12:51 ET | 100 | 16.46 |
12:55 ET | 500 | 16.46 |
01:00 ET | 397 | 16.41 |
01:04 ET | 100 | 16.4175 |
01:09 ET | 100 | 16.43 |
01:11 ET | 3400 | 16.35 |
01:13 ET | 320 | 16.37 |
01:20 ET | 100 | 16.415 |
01:22 ET | 200 | 16.39 |
01:24 ET | 756 | 16.47 |
01:29 ET | 100 | 16.51 |
01:31 ET | 100 | 16.485 |
01:33 ET | 800 | 16.52 |
01:36 ET | 700 | 16.58 |
01:38 ET | 100 | 16.585 |
01:40 ET | 300 | 16.61 |
01:42 ET | 700 | 16.67 |
01:44 ET | 500 | 16.59 |
01:51 ET | 300 | 16.62 |
01:56 ET | 200 | 16.61 |
01:58 ET | 200 | 16.61 |
02:00 ET | 500 | 16.62 |
02:02 ET | 400 | 16.64 |
02:03 ET | 1262 | 16.58 |
02:05 ET | 342 | 16.56 |
02:09 ET | 258 | 16.54 |
02:12 ET | 100 | 16.61 |
02:14 ET | 1204 | 16.59 |
02:16 ET | 434 | 16.59 |
02:20 ET | 903 | 16.62 |
02:21 ET | 200 | 16.66 |
02:23 ET | 200 | 16.67 |
02:25 ET | 417 | 16.67 |
02:27 ET | 700 | 16.67 |
02:30 ET | 4305 | 16.7 |
02:32 ET | 100 | 16.67 |
02:34 ET | 500 | 16.67 |
02:36 ET | 500 | 16.66 |
02:38 ET | 817 | 16.67 |
02:39 ET | 400 | 16.665 |
02:41 ET | 1600 | 16.75 |
02:43 ET | 1700 | 16.7575 |
02:45 ET | 1900 | 16.79 |
02:48 ET | 4857 | 16.88 |
02:50 ET | 1600 | 16.88 |
02:52 ET | 3459 | 16.88 |
02:54 ET | 2300 | 16.9 |
02:56 ET | 4765 | 16.96 |
02:57 ET | 8400 | 16.94 |
02:59 ET | 50747 | 16.92 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Corbus Pharmaceuticals Holdings Inc | 203.8M | -2.9x | --- |
Kodiak Sciences Inc | 202.0M | -1.0x | --- |
Gossamer Bio Inc | 197.7M | -2.2x | --- |
Kyverna Therapeutics Inc | 211.0M | 0.0x | --- |
PepGen Inc | 211.2M | -1.9x | --- |
CAMP4 Therapeutics Corp | 196.0M | -3.9x | --- |
Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio. The Company's pipeline is comprised of two experimental drugs targeting solid tumors: CRB-701, which is an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload and CRB-601, which is an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells. Its pipeline also includes CRB-913, which is a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. It has in-licensed the intellectual property for CRB-601 from Dr. Stephen Nishimura's laboratory at the University of California, San Francisco. The Company does not own or operate manufacturing facilities and relies on third-party contract manufacturing organizations or licensing partners to supply it with drugs for pre-clinical and clinical studies and commercial activities.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $203.8M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 12.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.59 |
EPS | $-5.82 |
Book Value | $-1.56 |
P/E Ratio | -2.9x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.